Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 3/2016

01-06-2016 | Review Article

Hepatocyte growth factor (HGF) and hemodialysis: physiopathology and clinical implications

Authors: Carmelo Libetta, Pasquale Esposito, Claudia Martinelli, Fabrizio Grosjean, Marilena Gregorini, Teresa Rampino, Antonio Dal Canton

Published in: Clinical and Experimental Nephrology | Issue 3/2016

Login to get access

Abstract

Hepatocyte growth factor (HGF) is a pleiotropic cytokine which exerts a variety of effects on several cells, being involved in the regulation of many biological processes, such as inflammation, tissue repair, morphogenesis, angiogenesis, tumour propagation, immunomodulation of viral infections and cardio-metabolic activities. Patients undergoing regular hemodialysis (HD) present elevated levels of HGF, mainly due to the leukocyte activation associated with HD treatment. High HGF levels might account for specific clinical features of HD patients, i.e. mild liver damage in course of HCV-infection and high cardiovascular risk profile. Moreover, in patients with acute kidney injury, the induction of HGF may represent a crucial step to promote renal recovery, which can have important prognostic consequences in the short and long-term. In this review we discuss the mechanisms underlying HGF production in HD patients, the role of HGF in this particular patient population and the potential clinical implications derived from the study of HGF in HD patients.
Literature
1.
Boros P, Miller CM. Hepatocyte growth factor: a multifunctional cytokine. Lancet. 1995;345:293–5.CrossRefPubMed
2.
Hamanoue M, Kawaida K, Takao S. Rapid and marked induction of hepatocyte growth factor during liver regeneration after ischemic or crush injury. Hepatology. 1992;16(6):1485–92.CrossRefPubMed
3.
Matsumoto K, Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int. 2001;59(6):2023–38.CrossRefPubMed
4.
Jin H, Wyss JM, Yang R, Schwall R. The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure. Curr Pharm Des. 2004;10(20):2525–33.CrossRefPubMed
5.
Rampino T, Libetta C, De SimoneW, Ranghino A, Soccio G, Gregorini M, Guallini P, Tamagnone L, Dal Canton A. Hemodialysis stimulates hepatocyte growth factor release. Kidney Int. 1998;53:1382–8.CrossRefPubMed
6.
Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987;327:239–42.CrossRefPubMed
7.
Nakamura T, Nawa K, Ichihara A, Kaise N, Nishino T. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett. 1997;224(2):311–6.CrossRef
8.
Weidner KM, Arakaki N, Hartmann G, Vandekerckhove J, Weingart S, Rieder H, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA. 1991;88(16):7001–5.CrossRefPubMedPubMedCentral
9.
Zarnegar R, Muga S, Rahija R, Michalopoulos G. Tissue distribution of hepatopoietin-A: a heparin-binding polypeptide growth factor for hepatocytes. Proc Natl Acad Sci USA. 1990;87(3):1252–6.CrossRefPubMedPubMedCentral
10.
Shimomura T, Kondo J, Ochiai M, Naka D, Miyazawa K, Morimoto Y, Kitamura N. Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem. 1993;268:22927–32.PubMed
11.
Shimomura T, Miyazawa K, Komiyama Y, Hiraoka H, Naka D, Morimoto Y, Kitamura N. Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator. Eur J Biochem. 1995;229:257–61.CrossRefPubMed
12.
Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-Met proto-oncogene product. Science. 1991;251:802–4.CrossRefPubMed
13.
Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude GF. Sequence of MET proto-oncogene cDNA has features characteristic of the tyrosine family of growth factor receptors. Proc Natl Acad Sci USA. 1987;84:6379–83.CrossRefPubMedPubMedCentral
14.
Zarnegar R. Regulation of HGF and HGFR gene expression. EXS. 1995;74:33–49.PubMed
15.
Matsumoto K, Tajima H, Hamanoue M, Kohno S, Kinoshita T, Nakamura T. Identification and characterization of “injurin”, an inducer of expression of the gene for hepatocyte growth factor. Proc Natl Acad Sci USA. 1992;89:3800–4.CrossRefPubMedPubMedCentral
16.
Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987;327:239–42.CrossRefPubMed
17.
Cañadas I, Taus A, González I, Villanueva X, Gimeno J, Pijuan L, Dómine M, Sánchez-Font A, Vollmer I, Menéndez S, Arpí O, Mojal S, Rojo F, Rovira A, Albanell J, Arriola E. High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients. Oncotarget. 2014;5(14):5246–56.CrossRefPubMedPubMedCentral
18.
Malatino LS, Mallamaci F, Benedetto FA, Bellanuova I, Cataliotti A, Tripepi G, Zoccali C. Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease. Am J Kidney Dis. 2000;36(5):945–52.CrossRefPubMed
19.
Lohr JW, Lee TP, Farooqui M, Mookerjee BK. Increased levels of serum hepatocyte growth factor in patients with end-stage renal disease. J Med. 2000;31(3–4):131–41.PubMed
20.
21.
Almroth G, Lönn J, Uhlin F, Nayeri F, Brudin L, Andersson B, Hahn-Zoric M. Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high-sensitivity C-reactive protein and soluble urokinase plasminogen activator receptor. Inflammation markers in chronic haemodialysis patients? Scand J Immunol. 2013;78(3):285–90.CrossRefPubMed
22.
Lee CT, Hsu CY, Lam KK, Lin CR, Chen JB. Inflammatory markers and hepatocyte growth factor in sustained hemodialysis hypotension. Artif Organs. 2005;29(12):980–3.CrossRefPubMed
23.
Borawski J, Naumnik B, Myśliwiec M. Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: role of heparin. Kidney Int. 2003;64(6):2229–37.CrossRefPubMed
24.
Christidou F, Bamichas G, Galaktidou G, Fragidis S, Gionanlis L, Frangia T, Bischiniotis T, Sombolos K. Elevated hepatocyte growth factor levels at the beginning of high-flux hemodialysis are due to heparin administration. Ren Fail. 2008;30(9):861–4.CrossRefPubMed
25.
Petrosillo N, Puro V, Ippolito G. Prevalence of human immunodeficiency virus, hepatitis B virus and hepatitis C virus among dialysis patients. The Italian Multicentric Study on Nosocomial and Occupational Risk of Blood-Borne Infections in Dialysis. Nephron. 1993;64(4):636–9.CrossRefPubMed
26.
Umlauft F, Gruenewald K, Weiss G, Kessler H, Urbanek M, Haun M, Santner B, Koenig P, Keeffe EB. Patterns of hepatitis C viremia in patients receiving hemodialysis. Am J Gastroenterol. 1997;92(1):73–8.PubMed
27.
Akpolat I, Ozyilkan E, Karagöz F, Akpolat T, Kandemir B. Hepatitis C in haemodialysis and nonuraemic patients: a histopathological study. Int Urol Nephrol. 1998;30(3):349–55.CrossRefPubMed
28.
Fabrizi F, Bunnapradist S, Lunghi G, Martin P. Kinetics of hepatitis C virus load during hemodialysis: novel perspectives. J Nephrol. 2003;16(4):467–75.PubMed
29.
Badalamenti S, Catania A, Lunghi G, Covini G, Bredi E, Brancaccio D, Salvadori M, Como G, Ponticelli C, Graziani G. Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus-positive patients: only coincidental phenomena? Am J Kidney Dis. 2003;42:143–50.CrossRefPubMed
30.
Fabrizi F, Messa P, Martin P. Impact of hemodialysis therapy on hepatitis C virus infection: a deeper insight. Int J Artif Organs. 2009;32(1):1–11.PubMed
31.
Marín-Serrano E, Rodríguez-Ramos C, Díaz-García F, Martín-Herrera L, Fernández-Gutiérrez-Del-Alamo C, Girón-González JA. Hepatocyte growth factor and chronic hepatitis C. Rev Esp Enferm Dig. 2010;102(6):365–71.CrossRefPubMed
32.
Kawaida K, Matsumoto K, Shimazu H, Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci USA. 1994;91:4357–61.CrossRefPubMedPubMedCentral
33.
Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, Matsumoto K, Nakamura T, Takahashi H, Okamoto E, Fujimoto J. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med. 1999;5:226–30.CrossRefPubMed
34.
Longati P, Albero D, Comoglio PM. Hepatocyte growth factor is a pleiotropic factor protecting epithelial cells from apoptosis. Cell Death Differ. 1996;3(1):23–8.PubMed
35.
Kosal K, Matsumoto K, Nagata S, Tsujimoto Y, Nakamura T. Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun. 1998;244:683–90.CrossRef
36.
Rampino T, Arbustini E, Gregorini M, Guallini P, Libetta C, Maggio M, Ranghino A, Silini E, Soccio G, Dal Canton A. Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor. Kidney Int. 1999;56(6):2286–91.CrossRefPubMed
37.
Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008;4(12):672–81.CrossRefPubMed
38.
Bevc S, Sabic S, Hojs R. Atherosclerosis in hemodialysis patients—the role of microinflammation. Ren Fail. 2008;30(10):1012–6.CrossRefPubMed
39.
Arechederra M, Carmona R, González-Nuñez M, Gutiérrez-Uzquiza A, Bragado P, Cruz-González I, Cano E, Guerrero C, Sánchez A, López-Novoa JM, Schneider MD, Maina F, Muñoz-Chápuli R, Porras A. Met signaling in cardiomyocytes is required for normal cardiac function in adult mice. Biochim Biophys Acta. 2013;1832(12):2204–15.CrossRefPubMed
40.
Chen XH, Minatoguchi S, Kosai K, Yuge K, Takahashi T, Arai M, Wang N, Misao Y, Lu C, Onogi H, Kobayashi H, Yasuda S, Ezaki M, Ushikoshi H, Takemura G, Fujiwara T, Fujiwara H. In vivo hepatocyte growth factor gene transfer reduces myocardial ischemia–reperfusion injury through its multiple actions. J Card Fail. 2007;13(10):874–83.CrossRefPubMed
41.
Shirakawa Y, Sawa Y, Takewa Y, Tatsumi E, Kaneda Y, Taenaka Y, Matsuda H. Gene transfection with human hepatocyte growth factor complementary DNA plasmids attenuates cardiac remodeling after acute myocardial infarction in goat hearts implanted with ventricular assist devices. J Thorac Cardiovasc Surg. 2005;130(3):624–32.CrossRefPubMed
42.
Sanada F, Taniyama Y, Azuma J, Iekushi K, Dosaka N, Yokoi T, Koibuchi N, Kusunoki H, Aizawa Y, Morishita R. Hepatocyte growth factor, but not vascular endothelial growth factor, attenuates angiotensin II-induced endothelial progenitor cell senescence. Hypertension. 2009;53(1):77–82.CrossRefPubMed
43.
Jin H, Wyss JM, Yang R, Schwall R. The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure. Curr Pharm Des. 2004;10:2525–33.CrossRefPubMed
44.
Lin JW, Sheu WH, Lee WJ, Chen YT, Liu TJ, Ting CT, Lee WL. Circulating hepatocyte growth factor level but not basic fibroblast growth factor level is elevated in angiography-proven symptomatic peripheral artery disease. Angiology. 2007;58(4):420–8.CrossRefPubMed
45.
Satani K, Konya H, Hamaguchi T, Umehara A, Katsuno T, Ishikawa T, Kohri K, Hasegawa Y, Suehiro A, Kakishita E, Namba M. Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with Type 2 diabetes. Diabet Med. 2006;23(6):617–22.CrossRefPubMed
46.
Malatino LS, Cataliotti A, Benedetto FA, Stancanelli B, Bellanuova I, Belluardo P, Bonaiuto L, Tripepi G, Mallamaci F, Castellino P, Zoccali C. Hepatocyte growth factor and left ventricular geometry in end-stage renal disease. Hypertension. 2003;41(1):88–92.CrossRefPubMed
47.
Anan F, Shimomura T, Imagawa M, Masaki T, Nawata T, Takahashi N, Yonemochi H, Eshima N, Saikawa T, Yoshimatsu H. Predictors for silent cerebral infarction in patients with chronic renal failure undergoing hemodialysis. Metabolism. 2007;56(5):593–8.CrossRefPubMed
48.
Chowdhury M, Ghosh J, Slevin M, Smyth JV, Alexander MY, Serracino-Inglott F. A comparative study of carotid atherosclerotic plaque microvessel density and angiogenic growth factor expression in symptomatic versus asymptomatic patients. Eur J Vasc Endovasc Surg. 2010;39:388–95.CrossRefPubMed
49.
Almroth G, Lönn J, Uhlin F, Brudin L, Andersson B, Hahn-Zoric M. Sclerostin, TNF-alpha and interleukin-18 correlate and are together with Klotho related to other growth factors and cytokines in hemodialysis patients. Scand J Immunol. 2015. doi:10.​1111/​sji.​12392 (PubMed PMID: 26448366).
50.
Rittig K, Dolderer JH, Balletshofer B, Machann J, Schick F, Meile T, Küper M, Stock UA, Staiger H, Machicao F, Schaller HE, Königsrainer A, Häring HU, Siegel-Axel DI. The secretion pattern of perivascular fat cells is different from that of subcutaneous and visceral fat cells. Diabetologia. 2012;55(5):1514–25.CrossRefPubMed
51.
Bonanni A, Mannucci I, Verzola D, Sofia A, Saffioti S, Gianetta E, Garibotto G. Protein-energy wasting and mortality in chronic kidney disease. Int J Environ Res Public Health. 2011;8(5):1631–54.CrossRefPubMedPubMedCentral
52.
Yuan J, Watanabe M, Suliman M, Qureshi AR, Axelsson J, Bárány P, Heimbürger O, Stenvinkel P, Lindholm B. Serum hepatocyte growth factor is associated with truncal fat mass and increased mortality in chronic kidney disease stage 5 patients with protein-energy wasting. Nephrol Dial Transplant. 2015;30(2):274–82.CrossRefPubMed
53.
Thakar CV, Christianson A, Freyberg R, Almenoff P, Render ML. Incidence and outcomes of acute kidney injury in intensive care units: a Veterans Administration study. Crit Care Med. 2009;37:2552–8.CrossRefPubMed
54.
Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 2011;79:1361–9.CrossRefPubMedPubMedCentral
55.
Igawa T, Matsumoto K, Kanda S, Saito Y, Nakamura T. Hepatocyte growth factor may function as a renotropic factor for regeneration in rats with acute renal injury. Am J Physiol. 1993;265(1 Pt 2):F61–9.PubMed
56.
Kawaida K, Matsumoto K, Shimazu N, Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci USA. 1994;91(10):4357–61.CrossRefPubMedPubMedCentral
57.
Nagano T, Mori-Kudo I, Kawamura T, Taiji M, Noguchi H. Pre- or post-treatment with hepatocyte growth factor prevents glycerol-induced acute renal failure. Ren Fail. 2004;26(1):5–11.CrossRefPubMed
58.
Fiaschi-Taesch NM, Santos S, Reddy V, Van Why SH, Philbrick WF, Ortega A, et al. Prevention of acute ischemic renal failure by targeted delivery of growth factors to the proximal tubule in transgenic mice: the efficacy of parathyroid hormone-related protein and hepatocyte growth factor. J Am Soc Nephrol. 2004;15(1):112–25.CrossRefPubMed
59.
Dworkin LD, Gong R, Tolbert E, Centracchio J, Yano N, Zanabli AR, Esparza A, Rifai A. Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. Kidney Int. 2004;65(2):409–19.CrossRefPubMed
60.
Tracz MJ, Alam J, Nath KA. Physiology and pathophysiology of heme: implications for kidney disease. J Am Soc Nephrol. 2007;18(2):414–20.CrossRefPubMed
61.
Gong R, Rifai A, Tolbert EM, Biswas P, Centracchio JN, Dworkin LD. Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and RANTES. J Am Soc Nephrol. 2004;15(11):2868–81.CrossRefPubMed
62.
Gregorini M, Bosio F, Rocca C, Corradetti V, Valsania T, Pattonieri EF, Esposito P, Bedino G, Collesi C, Libetta C, Frassoni F, Dal Canton A, Rampino T. Mesenchymal stromal cells reset the scatter factor system and cytokine network in experimental kidney transplantation. BMC Immunol. 2014;15:44.CrossRefPubMedPubMedCentral
63.
Libetta C, Rampino T, Esposito C, Fornoni A, Semeraro L, Dal Canton A. Stimulation of hepatocyte growth factor in human acute renal failure. Nephron. 1998;80(1):41–5.CrossRefPubMed
64.
Vaidya VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules C, Bradwin G, Matsouaka R, Betensky RA, Curhan GC, Bonventre JV. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci. 2008;1(3):200–8.CrossRefPubMedPubMedCentral
65.
Srisawat N, Murugan R, Wen X, Singbartl K, Clermont G, Eiam-Ong S, Kellum JA. Recovery from acute kidney injury: determinants and predictors. Contrib Nephrol. 2010;165:284–91.CrossRefPubMed
66.
Libetta C, Esposito P, Sepe V, Rampino T, Zucchi M, Canevari M, Dal Canton A. Acute kidney injury: effect of hemodialysis membrane on Hgf and recovery of renal function. Clin Biochem. 2013;46(1–2):103–8.CrossRefPubMed
67.
Hakim RM, Wingard RL, Parker RA. Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med. 1994;331(20):1338–42.CrossRefPubMed
68.
Memoli B, Postiglione L, Cianciaruso B, Bisesti V, Cimmaruta C, Marzano L, Minutolo R, Cuomo V, Guida B, Andreucci M, Rossi G. Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients. Kidney Int. 2000;58(1):417–24.CrossRefPubMed
Metadata
Title
Hepatocyte growth factor (HGF) and hemodialysis: physiopathology and clinical implications
Authors
Carmelo Libetta
Pasquale Esposito
Claudia Martinelli
Fabrizio Grosjean
Marilena Gregorini
Teresa Rampino
Antonio Dal Canton
Publication date
01-06-2016
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2016
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-015-1211-2

Other articles of this Issue 3/2016

Clinical and Experimental Nephrology 3/2016 Go to the issue

Guideline

Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014

Original Article

Tonsillectomy reduces recurrence of IgA nephropathy in mesangial hypercellularity type categorized by the Oxford classification

Original Article

DNA double-strand breaks induced intractable glomerular fibrosis in renal allografts

Original Article

A case series of acute renal infarction at a single center in Japan

Original Article

Impact of use of angiotensin II receptor blocker on all-cause mortality in hemodialysis patients: prospective cohort study using a propensity-score analysis

Images in Nephrology

Diffuse cortical calcification of failed kidney allograft
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits